poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC)
poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC) is the indication for 1 drug in DrugBank. It is covered by 2 curated, structured indications.
- Classified under
- Indicated drugs
What you can answer from here — as of October 22, 2026
1Indicated drugWith each drug's targets and mechanismListed above
2Structured indicationsPopulation, line of therapy, route and combination as fields, not proseSign in
Which approved drugs for poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC) share a target, and which companies have late-stage candidates against it?
Create a free account or log in to explore the full data card.
Create Account